LOXO Insider Trading Activity and SEC Form 4 Filings
LOXO insider trading summary
No open-market insider purchases or sales of Loxo Oncology, Inc. (LOXO) have been reported on SEC Form 4 in the past 12 months.
Latest LOXO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 13, 2018 | Avi Z. Naider | Director | Buy | $101K (725 @ $138.92) |
| Dec 11, 2018 | Naarden Jacob Van | Chief Business Officer | Sell | $69K (500 @ $137.73) |
| Dec 11, 2018 | Jennifer Burstein | Senior VP of Finance | Sell | $27K (200 @ $135.69) |
| Dec 11, 2018 | Jennifer Burstein | Senior VP of Finance | Sell | $36K (263 @ $137.88) |
| Dec 11, 2018 | Naarden Jacob Van | Chief Business Officer | Sell | $241K (1,759 @ $137.09) |
| Dec 11, 2018 | Jennifer Burstein | Senior VP of Finance | Sell | $14K (100 @ $139.36) |
| Dec 11, 2018 | Naarden Jacob Van | Chief Business Officer | Sell | $109K (800 @ $135.92) |
| Dec 11, 2018 | Jennifer Burstein | Senior VP of Finance | Sell | $80K (587 @ $136.98) |
| Dec 11, 2018 | Jennifer Burstein | Senior VP of Finance | Sell | $14K (100 @ $140.48) |
| Dec 11, 2018 | Naarden Jacob Van | Chief Business Officer | Sell | $54K (400 @ $134.74) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.